Ethical preparedness of data monitoring committees (DMCs) to oversee international clinical trials: a qualitative descriptive study

被引:0
|
作者
Hinga, Alex [1 ]
Ibrahim, Akram [2 ]
Vintimilla, Diego [3 ]
Jones, Mickayla [2 ]
Eckstein, Lisa [4 ]
Rid, Annette [5 ,6 ]
Shah, Seema K. [2 ,7 ]
Kamuya, Dorcas [1 ,8 ]
机构
[1] KEMRI Wellcome Trust Res Programme, Hlth Syst & Res Eth, Nairobi, Kenya
[2] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Mary Ann & J Milburn Smith Child Hlth Outcomes Res, Chicago, IL USA
[3] Chicago Dept Publ Hlth, Chicago, IL USA
[4] Univ Tasmania, Sch Law, Hobart, Tas, Australia
[5] NIH, Clin Ctr, Dept Bioeth, Bethesda, MD USA
[6] NIH, Fogarty Int Ctr, Div Int Sci Policy Planning & Evaluat, Bethesda, MD USA
[7] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
[8] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England
来源
BMJ GLOBAL HEALTH | 2024年 / 9卷 / 08期
基金
美国国家卫生研究院;
关键词
Global Health; Qualitative study; Clinical trial; Decision Making; Descriptive study; SAFETY; BOARDS; ISSUES;
D O I
10.1136/bmjgh-2024-015233
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction A data monitoring committee (DMC) is an independent group of experts who assess the ongoing scientific and ethical integrity of a study through periodic analyses of study data. The objective of this study was to explore the extent to which the structure, membership and deliberations of DMCs enable them to address ethical issues.Methods We conducted qualitative individual interviews (n=22) with DMC members from countries across Africa, the Americas, South Asia and the UK. We selected interview respondents through purposive sampling, managed data using NVivo (Release V.1.7) and analysed data thematically.Results All respondents were highly experienced professionals; many (18/22) had received training in medicine and/or statistics. One respondent had academic qualifications in ethics, and four indicated that they served on DMCs as ethicists. While respondents generally felt DMCs should be required for studies that were high-risk or enrolled vulnerable populations, some were concerned about the overuse of DMCs. There were divergent views on the necessity of geographical and disciplinary representation in DMC membership, including about whether ethicists were helpful. Many respondents described a DMC member recruitment process that they felt was somewhat exclusive. While one respondent received DMC-specific training, most described learning on the job. Respondents generally agreed that study protocols and DMC charters were key guiding documents for addressing ethical issues and described DMC deliberations that often, but not always, involved consensus-building.Conclusion This study is one of the first to consider the ethical implications of DMC structure, membership and deliberations. The potential overuse of DMCs, DMC member recruitment processes that seem somewhat insular, limited training for DMC members, and divergent approaches to deliberation may limit the capacity of DMCs for addressing ethical issues. Further research on DMC structure and processes could help enhance the ethical preparedness of DMCs.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] DATA MONITORING COMMITTEES FOR MULTICENTER CLINICAL-TRIALS SPONSORED BY THE NATIONAL-INSTITUTES-OF-HEALTH .1. ROLES AND MEMBERSHIP OF DATA MONITORING COMMITTEES FOR TRIALS SPONSORED BY THE NATIONAL-EYE-INSTITUTE
    HAWKINS, BS
    CONTROLLED CLINICAL TRIALS, 1991, 12 (03): : 424 - 437
  • [32] Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials
    Tharmanathan, P.
    Calvert, M. J.
    Freemantle, N.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (02) : 111 - 118
  • [33] A SYSTEMATIC REVIEW OF THE REPORTING OF DATA MONITORING COMMITTEES, INTERIM ANALYSIS AND EARLY TERMINATION IN PEDIATRIC CLINICAL TRIALS
    Fernandes, R.
    van der Lee, J. H.
    Offringa, M.
    ACTA PAEDIATRICA, 2009, 98 : 19 - 19
  • [34] Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute
    Smith, MA
    Ungerleider, RS
    Korn, EL
    Rubinstein, L
    Simon, R
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2736 - 2743
  • [35] Presence and independence of data safety monitoring and executive committees in industry-sponsored clinical trials.
    Lucas, BD
    Reyes, B
    Elhabyan, AK
    Blackwood, H
    Lipton, J
    Brewer, E
    PHARMACOTHERAPY, 2005, 25 (03): : 472 - 472
  • [36] Data capture by digital pen in clinical trials: A qualitative and quantitative study
    Estellat, Candice
    Tubach, Florence
    Costa, Yolande
    Hoffmann, Isabelle
    Mantz, Jean
    Ravaud, Philippe
    CONTEMPORARY CLINICAL TRIALS, 2008, 29 (03) : 314 - 323
  • [37] A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials
    Ricardo M Fernandes
    Johanna H van der Lee
    Martin Offringa
    BMC Pediatrics, 9
  • [38] A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials
    Fernandes, Ricardo M.
    van der Lee, Johanna H.
    Offringa, Martin
    BMC PEDIATRICS, 2009, 9
  • [39] Researchers experience and views on participants' comprehension of informed consent in clinical trials in Malawi: a descriptive qualitative study
    Kazembe, Dorothy Maxwell
    Woldeamanuel, Yimtubezinash
    Abay, Solomon Mequanente
    BMC MEDICAL ETHICS, 2024, 25 (01):
  • [40] "You have to keep your nerve on a DMC." Challenges for data monitoring committees in neonatal intensive care trials: qualitative accounts from the bracelet study
    Snowdon, Claire
    Elbourne, Diana
    Brocklehurst, Peter
    Platt, Martin Ward
    Tasker, Robert
    TRIALS, 2015, 16